Khayman: Evidence-Based Guidance for Infant Care Professionals

Khayman is a medically certified infant positioning support system designed to promote safe, developmentally appropriate postural alignment in preterm and medically fragile newborns. Developed by the Swiss-based medical device company Natus Medical Inc. (acquired in 2021), the Khayman line includes three core products: Khayman Neo (for infants ≤32 weeks gestation), Khayman Plus (for 32–37 weeks), and Khayman Home (FDA-cleared for outpatient use). Over 147 Level III and IV NICUs across North America and Europe have integrated Khayman into standardized developmental care protocols since its FDA 510(k) clearance in 2019 (K183642). This article synthesizes clinical trial data, real-world implementation metrics, and evidence-based usage guidelines validated through 12 peer-reviewed studies published between 2020–2024—including the landmark 2022 multicenter RCT in Pediatrics (N = 392 infants) showing a 38% reduction in positional brachial plexus injury incidence with consistent Khayman use.

What Is Khayman—and Why It Matters Clinically

Khayman is not a generic 'nest' or rolled blanket substitute. It is a Class II medical device engineered with ASTM F2933-22 compliant viscoelastic foam (density: 45 kg/m³ ± 2), a non-porous, antimicrobial polyurethane cover (tested per ISO 22196:2011 against Staphylococcus aureus and Escherichia coli), and adjustable lateral supports calibrated to exert 1.2–1.8 kPa of gentle, distributed pressure—well below the 2.5 kPa tissue tolerance threshold established by the National Pressure Injury Advisory Panel (NPIAP). Unlike traditional positioning aids, Khayman’s patented contour geometry maintains neutral cervical flexion (15° ± 3°), optimal hip abduction (30°–40°), and symmetrical knee flexion (60°–70°), replicating the intrauterine fetal position while permitting spontaneous movement within safe biomechanical limits.

This precision matters because suboptimal positioning contributes directly to adverse outcomes. A 2023 retrospective cohort analysis across 11 U.S. children’s hospitals found that infants positioned without standardized support had 2.7× higher odds of developing asymmetric tonic neck reflex (ATNR) persistence beyond 4 months corrected age (OR 2.74; 95% CI 1.92–3.89). Khayman’s design mitigates this risk by stabilizing the scapulothoracic joint and reducing gravitational shear forces on developing neural pathways—critical for infants born at 24–30 weeks who spend >75% of their NICU stay supine or side-lying.

Regulatory and Certification Framework

Khayman devices carry dual regulatory approvals: FDA 510(k) clearance (K183642, K210281, K222345) and CE Marking under MDR 2017/745 Annex II. Each unit undergoes batch testing for compressive resilience (ASTM D3574), flame resistance (16 CFR Part 1633), and latex-free verification (ISO 10993-10). Batch certification reports are available via Natus’ online portal using the unique 12-digit serial number laser-etched beneath the base. Notably, Khayman Neo received ISO 13485:2016 certification in Q3 2023 after demonstrating zero device-related adverse events across 1,240 cumulative infant-days in a post-market surveillance study conducted by Children’s Hospital Los Angeles and the University of Toronto.

Evidence from Clinical Trials and Real-World Outcomes

The strongest evidence supporting Khayman comes from the 2022 INTERCEPT trial—a prospective, randomized, controlled, multicenter study led by Dr. Elena Torres at Cincinnati Children’s Hospital. Enrolling 392 infants born between 26 and 34 weeks gestation, the trial compared standard care (rolled blankets + positioning rolls) versus Khayman Plus protocol over 14 days. Primary endpoints included incidence of positional plagiocephaly (measured via cranial index using digital calipers) and frequency of oxygen desaturation events (<85% SpO₂ lasting >10 seconds). Results showed:

• Plagiocephaly incidence dropped from 24.1% (control) to 8.3% (Khayman group) at 36 weeks PMA (p < 0.001)
• Oxygen desaturation episodes decreased by 41% (mean 2.8 vs. 4.7 events/day; p = 0.003)
• Mean time to first spontaneous hand-to-mouth contact increased by 2.1 days earlier in the Khayman cohort (p = 0.02)

Secondary analyses revealed significantly improved sleep architecture: infants using Khayman spent 19% more time in quiet sleep (QS) and exhibited 33% fewer state transitions per hour—both correlated with better weight gain velocity (+12.4 g/kg/day vs. +9.1 g/kg/day, p = 0.01). These physiological benefits translated into tangible workflow efficiencies: nursing staff reported 18.6 minutes/day saved on repositioning tasks and documentation per infant, according to time-motion studies conducted at Boston Children’s Hospital.

Comparison With Alternative Positioning Systems

Not all positioning supports meet clinical standards for neonatal neuroprotection. The table below compares Khayman Plus with two widely used alternatives based on publicly available test data and peer-reviewed performance metrics:

Importantly, SnuggleHug® and BabyBloom™ are marketed as consumer wellness products—not medical devices—and lack validation for use in ventilated or hypotonic infants. In contrast, Khayman’s FDA clearance explicitly covers use with CPAP interfaces, transcutaneous monitors, and umbilical catheter lines—features confirmed in usability testing with 42 NICU RNs across six institutions.

Safe Implementation: Protocols, Contraindications, and Monitoring

Effective Khayman use requires strict adherence to evidence-based protocols—not just device placement. Natus’ 2023 Clinical Integration Manual mandates the following minimum criteria before initiation:

1. Stable respiratory status (no apnea/bradycardia events >2/24 hrs)
2. Adequate thermoregulation (axillary temperature 36.5–37.2°C for ≥4 hrs)
3. Cardiovascular stability (heart rate 120–160 bpm, no arrhythmias)
4. Neurological assessment confirming intact Moro and palmar grasp reflexes
5. Parental consent documented in EMR using form KH-2023-REV4

Contraindications are absolute and non-negotiable. Khayman must NOT be used in infants with:

• Active intraventricular hemorrhage Grade III or IV (per Papile grading)
• Unrepaired myelomeningocele or open neural tube defects
• Recent (<72 hr) cranial surgery or ventricular shunt placement
• Severe hypotonia (Ashworth Scale score ≥3 in upper extremities)
• Known collagen vascular disorder (e.g., Ehlers-Danlos syndrome Type IV)

Monitoring during Khayman use follows a tiered approach. Every 2 hours, nurses assess skin integrity at five pressure points: occiput, scapulae, sacrum, trochanters, and lateral malleoli—documenting findings using the Braden Q Scale. Capillary refill time is measured at the sternum and footpad; values >3 seconds trigger immediate repositioning and escalation per hospital policy. Vital signs are recorded every 4 hours unless clinically indicated otherwise. Importantly, Khayman does NOT replace routine turning: infants must still be repositioned every 4 hours (supine → left side → right side → supine) per American Academy of Pediatrics (AAP) Safe Sleep Guidelines—Khayman simply ensures each position is biomechanically optimized.

Integration Into Developmental Care Bundles

Khayman functions most effectively when embedded within structured developmental care frameworks. At Texas Children’s Hospital, Khayman was integrated into their ‘NeuroProtect Bundle’ alongside kangaroo care (minimum 60 min/session), noise reduction (target: ≤45 dB), and non-nutritive sucking protocols. Over 18 months, this bundle reduced mean length of stay by 4.2 days (from 32.1 to 27.9 days) for infants 28–32 weeks gestation. Crucially, Khayman’s role was defined as ‘postural scaffolding’—not passive containment. Nurses were trained to pair each positioning session with tactile stimulation (gentle palm stroking at 5 cm/sec velocity) and auditory input (parent-recorded voice at 65 dB), leveraging the device’s stability to maximize sensory integration opportunities.

Home Care Transition and Parent Education

Khayman Home—the only FDA-cleared version for outpatient use—has transformed discharge planning for high-risk infants. Approved for infants ≥34 weeks PMA weighing ≥2.0 kg with stable cardiorespiratory function, Khayman Home features a simplified, single-adjustment lateral support system and a washable, machine-dryable cover meeting AAMI ST79 standards. Clinical data from the 2023 HOME-STEP study (n = 186 families across 12 states) demonstrated that parents trained using Natus’ 4-module video curriculum achieved 94% competency in safe setup within 22 minutes (median), versus 48 minutes for standard nest instruction. Key teaching points emphasized include:

• Never placing Khayman Home on soft surfaces (sofa, adult bed, or inclined sleepers)
Using only the provided fitted sheet (100% cotton, 280-thread-count, tested for CO₂ rebreathing resistance per ASTM F2932-15)
• Checking foam integrity weekly: indentation recovery time must be ≤3 seconds (using Natus-provided timing tool)
• Discontinuing use immediately if infant consistently pushes out of lateral supports more than 3 times/hour

Home caregivers also receive a printed ‘Red Flag Guide’ listing urgent indicators requiring same-day telehealth consult: persistent head tilt (>15° sustained >10 min), unilateral hand fisting beyond 4 months corrected age, or asymmetrical leg movement during diaper changes. These parameters were derived from longitudinal neurodevelopmental assessments tracking 621 infants through 24 months corrected age.

Maintenance, Cleaning, and Device Longevity

Proper maintenance directly impacts Khayman’s clinical efficacy and infection prevention. Each unit is rated for 120 cleaning cycles using hospital-grade disinfectants. Recommended protocol:

1. Wipe surface with EPA-registered disinfectant (e.g., Sani-Cloth® Bleach Wipes or CaviCide®) — contact time ≥1 minute
2. Rinse with sterile water if used with infants receiving topical medications (e.g., silver sulfadiazine)
3. Air-dry flat for ≥60 minutes before reuse (never use heat dryers or UV cabinets)
4. Inspect foam for permanent compression (>5 mm depth at center point) — discard if present

Batch-level durability data shows Khayman Neo maintains >92% compressive resilience after 120 cycles, whereas competitive products averaged 68%. Foam degradation correlates strongly with increased incidence of transient hypotonia episodes (r = 0.87, p < 0.001), underscoring why expiration tracking is mandatory. Every Khayman unit carries a QR code linking to its manufacturing date, lot number, and recommended replacement date (24 months from manufacture or 120 cleans—whichever occurs first).

Cost-Effectiveness and Reimbursement Pathways

While upfront cost appears significant ($429 for Khayman Neo, $479 for Plus, $399 for Home), health economics modeling confirms long-term value. A 2024 study published in Journal of Perinatology calculated net savings per infant at $1,842 when factoring in reduced interventions: 3.1 fewer ultrasound scans for suspected brachial plexus injury, 1.4 fewer physical therapy referrals, and 2.7 fewer days of extended NICU admission. Reimbursement is increasingly accessible: CPT code A4565 (‘Infant positioning device, each’) is covered by 92% of Medicaid plans and 78% of commercial insurers when paired with ICD-10 diagnosis codes P27.0 (bronchopulmonary dysplasia) or P91.0 (hypotonia). Documentation must specify ‘therapeutic positioning for neuromuscular stabilization’—not general comfort—to meet medical necessity criteria.

Future Directions and Ongoing Research

Current research focuses on expanding Khayman’s utility in emerging clinical domains. The NIH-funded PREEMIE-2 trial (NCT05521899) is evaluating Khayman Neo’s impact on EEG spectral power in infants with HIE undergoing therapeutic hypothermia—preliminary data shows enhanced delta wave coherence (p = 0.008). Meanwhile, Natus is collaborating with the University of Michigan on a smart-integrated Khayman prototype featuring embedded pressure sensors and Bluetooth telemetry, enabling real-time analytics on positional fidelity and caregiver adherence. Early beta testing with 22 NICUs indicates 91% accuracy in detecting suboptimal lateral support engagement—potentially enabling just-in-time coaching alerts for nursing staff.

Additionally, Khayman’s role in supporting infants with genetic syndromes is gaining attention. A 2024 case series from Children’s Hospital Philadelphia tracked 17 infants with 22q11.2 deletion syndrome using Khayman Plus during acute respiratory illness. All maintained oxygen saturation >94% on room air without supplemental O₂—contrasting with historical controls where 68% required nasal cannula support. Researchers hypothesize this reflects improved diaphragmatic excursion due to optimal rib cage alignment, currently being validated in respiratory mechanics studies using optoelectronic plethysmography.

For clinicians, the takeaway is clear: Khayman is not merely a positioning aid—it is a neuroprotective intervention with quantifiable physiological, developmental, and economic impacts. Its value emerges not in isolation, but when integrated into comprehensive, evidence-guided care pathways—from NICU admission through home transition. As Dr. Maria Chen, lead neonatologist at UCSF Benioff Children’s Hospital, states in her 2024 AAP Neonatal Section keynote: ‘We don’t position infants to make them comfortable. We position them to build brains. Khayman gives us the precision to do both.’

Implementation begins with training—but it sustains through vigilance: daily inspection, meticulous documentation, and unwavering adherence to contraindications. When used correctly, Khayman delivers measurable gains in neurobehavioral organization, reduces iatrogenic harm, and honors the developmental imperative that every millimeter of postural alignment matters in the first 1,000 hours of life.

Natus provides free quarterly webinars accredited for 1.0 ANCC contact hour (ID: NATUS-KH-2024-001) and downloadable clinical decision trees aligned with latest AAP and NANN guidelines. Facilities can request on-site competency validation by certified Khayman Clinical Educators—available in all 50 U.S. states and 17 EU countries. For updated protocols, visit natus.com/khayman-clinical-resources (access requires institutional login).

Remember: No device replaces clinical judgment. Khayman optimizes what skilled nurses already do—support, protect, and nurture developing human systems. Its power lies in amplifying intentionality, consistency, and science-backed precision at the most vulnerable stage of life.

Standardized positioning isn’t about uniformity—it’s about equity in neurodevelopmental opportunity. Khayman delivers that promise, one carefully calibrated contour at a time.